Analysts Set Esperion Therapeutics Inc (NASDAQ:ESPR) Price Target at $72.77

Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have received a consensus rating of “Buy” from the sixteen ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $72.69.

A number of research analysts have issued reports on the company. Credit Suisse Group restated a “buy” rating and issued a $87.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, June 9th. Northland Securities assumed coverage on Esperion Therapeutics in a research note on Tuesday. They issued a “hold” rating and a $42.00 price objective for the company. Jefferies Financial Group reduced their price objective on Esperion Therapeutics from $85.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. ValuEngine raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 21st. Finally, Citigroup upped their price target on Esperion Therapeutics from $46.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, May 7th.

Esperion Therapeutics stock traded down $1.07 during trading on Friday, hitting $45.90. 764,823 shares of the company were exchanged, compared to its average volume of 684,292. The company has a market capitalization of $1.30 billion, a P/E ratio of -4.77 and a beta of 2.16. The company has a current ratio of 2.35, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $44.50 and its 200 day moving average is $48.22. Esperion Therapeutics has a 52 week low of $24.82 and a 52 week high of $76.98.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.14) by $0.30. The firm had revenue of $1.80 million during the quarter, compared to the consensus estimate of $0.39 million. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. The business’s revenue for the quarter was down 98.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.07 EPS. Equities analysts expect that Esperion Therapeutics will post -4.95 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in Esperion Therapeutics during the 1st quarter worth about $43,000. PNC Financial Services Group Inc. increased its stake in Esperion Therapeutics by 32,833.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,976 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Esperion Therapeutics by 59.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,159 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 808 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Esperion Therapeutics by 68.1% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,348 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 546 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Esperion Therapeutics by 21.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,361 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 238 shares during the last quarter.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Diversification

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.